132 results about "Anti sense" patented technology

Provided is a circular multimeric tandem RNA sense strand, comprising at least one sense strand sequence and at least one spacer sequence. The circular RNA is derived from an engineered parental DNA template containing all essential sequences, and sequentially comprises a first cyclization element, optionally at least one first restriction enzyme recognition sequence, at least one target sequence, optionally at least one second restriction enzyme recognition sequence, and a second cyclization element. The circular multimeric tandem RNA sense strand can bind and deliver a plurality of antisense strand RNA, increasing the binding of the sense strand and the antisense strand while utilizing the stability advantage of circular RNA.

Provided are an INHBE gene-targeted double-stranded oligonucleotide, a conjugate, and a composition, which relate to the technical field of nucleic acid drugs. The double-stranded oligonucleotide comprises a sense strand and an antisense strand. The antisense strand is complementary or substantially complementary to the sense strand; the sense strand comprises a nucleotide sequence identical or substantially identical to at least 15 consecutive nucleotides in a sequence of SEQ ID NO: 309, and said substantially identical means that there is no more than three nucleotide differences between the sense strand and the at least 15 consecutive nucleotides in the sequence of SEQ ID NO: 309. The double-stranded oligonucleotide can effectively inhibit the INHBE gene and treat patients suffering from metabolic diseases or metabolic syndrome and related diseases such as diabetes, hypertension and cardiovascular diseases.

The invention provides annular multi-tandem PCSK9 siRNA, which comprises at least one positive-sense strand sequence and at least one spacer sequence. The sense strand of the cyclic siRNA is derived from an engineered parent DNA template containing all essential sequences, comprising in the following order a first cyclization element, optionally at least one first restriction enzyme recognition sequence, at least one target sequence, optionally at least one second restriction enzyme recognition sequence, and a second cyclization element. The annular multi-tandem RNA positive-sense strand can combine and deliver a plurality of antisense strand RNAs, and the combination of the positive-sense strand and the antisense strand is increased while the stability advantage of the annular RNA is utilized.

The present invention relates to a nucleic acid molecule inhibiting factor 11 (FXI) gene expression in a cell by means of RNAi, comprising a sense sequence and an antisense sequence complementary to each other, or consisting of a sense sequence and an antisense sequence complementary to each other. The FXI inhibition rate of the nucleic acid molecule is significantly superior to that of other small nucleic acid molecules which inhibit the expression of FXI by means of RNAi.

Provided is a circular concatemeric PCSK9 siRNA, comprising at least one sense strand sequence and at least one spacer sequence. The sense strand of the circular siRNA is derived from an engineered parental DNA template containing all essential sequences, which comprises, in the following order: a first cyclization element, optionally at least one first restriction enzyme recognition sequence, at least one target sequence, optionally at least one second restriction enzyme recognition sequence, and a second cyclization element. The sense strand of the circular concatemeric RNA can bind and deliver a plurality of antisense strand RNAs, enhancing the binding between the sense and antisense strands while leveraging the stability advantage of the circular RNA.

The present disclosure provides compositions and methods for accurately detecting mutations by uniquely tagging double stranded nucleic acid molecules with dual cyphers such that sequence data obtained from a sense strand can be linked to sequence data obtained from an anti-sense strand when sequenced, for example, by massively parallel sequencing methods.

A double-stranded oligonucleotide and a use thereof in inhibiting the expression of angiotensinogen (AGT). The double-stranded oligonucleotide comprises a sense strand and an antisense strand; the antisense strand contains a nucleotide sequence comprising at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 contiguous nucleotides of any sequence in SEQ ID NO: 225-SEQ ID NO: 448, or contains a nucleotide sequence which differs from the contiguous nucleotides by 1, 2, or 3 nucleotide(s).

Provided siRNA for inhibiting XDH gene expression and a modifier and use thereof. The siRNA comprises a sense strand and an antisense strand. The sense strand and / or the antisense strand have a length in the range of 19-25 nucleotides, and the antisense strand is reversely complementary to a segment on a target gene; and the sense strand has a nucleotide sequence as shown in SEQ ID NO: 1-14, and the antisense strand has a nucleotide sequence as shown in SEQ ID NO: 18-31. siRNA molecules and modified siRNA molecules have high stability and / or high inhibitory activity. Ligand-conjugated siRNA molecules have good liver targeting performance and the capability to promote cell endocytosis while maintaining high inhibitory activity and stability, can reduce the impact on other tissues or organs and reduce the amount of siRNA molecules used, and can achieve the purposes of reducing toxicity and reducing costs.

The invention relates to a nucleic acid, a pharmaceutical composition containing the nucleic acid, a conjugate containing the nucleic acid and application of the nucleic acid. Specifically, the invention relates to siRNA which has complementary positive-sense strand and antisense strand, each nucleotide in the siRNA is independently modified or unmodified nucleotide, and the siRNA is characterized in that the positive-sense strand of the siRNA contains a sequence SEQ ID NO: 1, 21 or 23 or a sequence which is similar to the sequence SEQ ID NO: 1, 21 or 23 by four nucleotides, and the antisense strand of the siRNA contains a sequence SEQ ID NO: 2, 22 or 24 or a sequence which is similar to the sequence SEQ ID NO: 2, 22 or 24 by four nucleotides. The invention also provides a nucleic acid group comprising the nucleic acid as a first siRNA and a second siRNA comprising a sense strand comprising the sequence of SEQ ID NO: 5, 7 or 43 and an antisense strand comprising the sequence of SEQ ID NO: 6, 8 or 44, a pharmaceutical composition and a conjugate comprising the nucleic acid or the nucleic acid group, and applications thereof.

A double-stranded siRNA for inhibiting PNPLA3 expression and a conjugate comprising same. The double-stranded siRNA comprises a sense strand and an antisense strand, wherein one or more nucleotide residues in a nucleotide sequence of the sense strand and / or the antisense strand are replaced with r1 represented by formula I: formula (I). The introduction of a non-natural nucleotide monomer into the double-stranded siRNA improves the target selectivity and activity of the siRNA sequence, reducing the off-target risk while maintaining high drug activity. Also provided is a tetravalent GalNAc, making it easier to scale up synthesis and reduce costs.

The present invention relates to the technical field of nucleic acid drugs. Disclosed are a double-stranded oligonucleotide inhibiting LPA gene expression and the use thereof. The double-stranded oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand contains a nucleotide sequence that is identical or substantially identical to at least 15 consecutive nucleotides in the sequence as shown in SEQ ID NO. 1, and the antisense strand contains at least 17 nucleotides and is complementary or substantially complementary to the sense strand to form a duplex region. Each nucleotide of the double-stranded oligonucleotide is independently selected from unmodified or modified nucleotides. The double-stranded oligonucleotide can inhibit LPA gene expression and solve the problem of an siRNA drug for treating LPA gene expression related diseases such as cardiovascular and cerebrovascular diseases.

The invention discloses siRNA (small interfering Ribonucleic Acid) targeting TMEM86A and application thereof, and relates to the technical field of biology, the siRNA comprises the following positive-sense strands and antisense strands: siRNA-001: a positive-sense strand: 5 '-GAAGAGCGAAGGACCCAAATT-3'; according to the tumor-associated macrophage, TMEM86A has a positive-sense strand of 5 '-TTTGGGTCCTTCGCTTCT-3', an antisense strand of 5 '-TTTGGGTCCTGTCGCTTCT-3', siRNA-002 has a positive-sense strand of 5 '-GGCTCATGGTTCGGTTTT-3', and an antisense strand of 5 '-AAACCGAACCCATGAGCCT-3'. According to the tumor-associated macrophage, single cell sequencing analysis finds that TMEM86A is highly expressed in tumor-associated macrophages, and the development of tumors is inhibited by designing siRNA of TMEM86A to target the tumor-associated macrophages in a colon cancer tumor microenvironment.

An siRNA capable of inhibiting the expression of apolipoprotein C3 (APOC3) gene, comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand are respectively composed of nucleotide sequence I or nucleotide sequence II comprising 19 modified or unmodified nucleotides, and the nucleotide sequence I and the nucleotide sequence II are at least partially reverse complementary to form a double-stranded region, and the nucleotide sequence II is at least partially reverse complementary to a nucleotide sequence segment in the mRNA of APOC3 gene expression; in the direction from the 5'-end to the 3'-end, at least one of the 3-6th nucleotides of the nucleotide sequence II is a stabilized modified nucleotide. The siRNA as described above, as well as the pharmaceutical composition and siRNA conjugate comprising the siRNA, can effectively treat and / or prevent diseases or disorders related to APOC3 gene expression, and have a significantly reduced off-target effect.

The invention generally relates to capturing, amplifying, and sequencing nucleic acids. In certain embodiments, copies of the sense and antisense strands of a duplex template nucleic acid are captured using linked capture probes and multiple binding and extension steps to improve specificity over traditional single binding target capture techniques. Methods of seeding sequencing clusters with sense and antisense strands of a target nucleic acid are also disclosed including identifying the strands using sense-specific barcodes and confirming base calls using two sense-specific sequencing reads. Linked adapters may be used to increase adapter ligation selectively or efficiency and yield.

This invention discloses five RNAi molecules targeting the genome of the small cutworm, all of which are double-stranded RNA molecules composed of a sense strand and a complementary antisense strand, wherein the nucleotide sequence of the sense strand is selected from SEQ ID NOs:1-5. The lethality of these RNAi molecules against the small cutworm is all above 80%.

Double-stranded ribonucleic acid (dsRNAi) agents that target exon 1 of the huntingtin (HTT) gene are provided.SOLUTION: A double-stranded ribonucleic acid (dsRNA) agent for inhibiting the expression of huntingtin (HTT), the agent comprising a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from a certain specific nucleotide sequence, and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from another certain specific nucleotide sequence, provided are dsRNA agents wherein one or more lipophilic moieties are conjugated to one or more internal positions on at least one of the sense or antisense strands.SELECTED DRAWING: None

The present application relates to a nucleic acid molecule inhibiting ANGPTL3 gene expression. The nucleic acid molecule contains or consists of substantially complementary sense and antisense sequences, wherein the sense sequence and / or antisense sequence has a nucleotide length of 14-30 nt. The nucleic acid molecule can better specifically silence an ANGPTL3 gene.

Provided herein is a double-stranded oligonucleotide agent capable of activating or up-regulating the expression of a target gene, comprising a sense strand and an antisense strand, each strand with 15 to 35 nucleotides in length, wherein the sense strand and the antisense strand are at least 50% complementary to each other, forming a duplex structure of at least 8 base pairs, wherein the double-stranded oligonucleotide agent comprises one or more glycerol nucleic acid (GNA) modified nucleotides located in either or both of the sense strand and the antisense strand.

The invention relates to a double-stranded (ds) ribonucleic acid (RNA) comprising a sense strand and an antisense strand in which the sense strand comprises the nucleotide sequence SEQ ID NO: 7 and the antisense strand comprises the nucleotide sequence SEQ ID NO: 8. The invention also relates to the dsRNA according to the invention for its use as a medicament.

This invention belongs to the field of biomedicine, specifically relating to siRNA targeting the angiopoietin-like protein 3 gene and its applications. The siRNA comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand are at least partially anticomplementary to form a double-stranded region. The sense strand or antisense strand consists of a 19-nucleotide blunt-ended complementary nucleotide sequence; or a sense strand of 19 nucleotides and an antisense strand of 21 nucleotides with overhanging ends. The siRNA of this invention can comprehensively lower blood lipids, and has good lipid-lowering effects on triglycerides and LDL-C, helping to significantly reduce the risk of atherosclerosis and cardiovascular disease.

The invention generally relates to capturing, amplifying, and sequencing nucleic acids. In certain embodiments, copies of the sense and antisense strands of a duplex template nucleic acid are captured using linked capture probes and multiple binding and extension steps to improve specificity over traditional single binding target capture techniques. Methods of seeding sequencing clusters with sense and antisense strands of a target nucleic acid are also disclosed including identifying the strands using sense-specific barcodes and confirming base calls using two sense-specific sequencing reads. Linked adapters may be used to increase adapter ligation selectively or efficiency and yield.

Provided herein are double-stranded nucleic acid inhibitor molecules having a shortened sense strand with a stem loop structure and an antisense strand. Also provided are methods and compositions for reducing target gene expression and methods and compositions for treating a disease of interest.

The present invention relates to a nucleic acid molecule that inhibits intracellular factor 11 (FXI) gene expression via RNAi, comprising mutually complementary sense sequences and antisense sequences or composed of mutually complementary sense sequences and antisense sequences, and the inhibition rate of said nucleic acid molecule against FXI is significantly superior to that of other small nucleic acid molecules that inhibit FXI expression via RNAi.

This application relates to the field of biotechnology, and particularly to Arg1-targeting double-stranded oligonucleotides and their conjugates, pharmaceutical compositions, and their application in pulmonary fibrosis. The Arg1-targeting double-stranded oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand are at least partially anticomplementary to form a double-stranded region; the nucleotide sequence of the sense strand comprises a sequence differing from the sequence shown in SEQ ID NO.1 by no more than 3 nucleotides, and the nucleotide sequence of the antisense strand comprises a sequence differing from the sequence shown in SEQ ID NO.2 by no more than 3 nucleotides. Using this Arg1-targeting double-stranded oligonucleotide and its conjugates, or pharmaceutical compositions containing it, to reprogram the nucleic acid of M2 macrophages in pulmonary fibrosis can effectively alter their pro-fibrotic functional state.

Provided is an siRNA that inhibits the expression of an RAGE gene, which siRNA comprises a sense strand and an antisense strand. The provided siRNA has good stability and can be used for efficiently and specifically inhibiting the expression of the RAGE gene, thereby providing important clinical value in the treatment of RAGE-related diseases.

This invention belongs to the field of biomedicine, specifically relating to siRNA that inhibits AR gene expression, comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand are at least partially anticomplementary to form a double-stranded region, and the sense strand or antisense strand consists of 19-25 nucleotides with blunt ends of complementary nucleotide sequences; or the antisense strand consists of 27 nucleotide sequences with overhangs. The siRNA of this invention can maintain long-term efficacy with a single dose, exhibiting good compliance in patients with chronic diseases such as androgenetic alopecia. Furthermore, it has lower off-target toxicity and fewer side effects compared to small molecule chemical drugs and hormone drugs.

To provide an siRNA and a pharmaceutical composition which inhibit kininogen (KNG) expression and thus can achieve the purpose of effectively inhibiting a life span of a pathogen so as to alleviate the progress of the septicemia and reverse the pathology.SOLUTION: The siRNA contains a sense strand and an antisense strand. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide. Lengths of the sense strand and the antisense strand are the same or different, the length of the sense strand is 19-23 nucleotides, and the length of the antisense strand is 19-26 nucleotides. The sense strand contains a specific nucleotide sequence I. The antisense strand contains a specific nucleotide sequence II. The nucleotide sequence I and the nucleotide sequence II form a substantially reverse complementary or completely reverse complementary double-stranded region. The siRNA inhibits expression of a kininogen gene in hepatocytes.SELECTED DRAWING: Figure 3

Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant or reduced protein expression, and therapeutic agents which can target the alternative splicing events in the genes can modulate the expression level of functional proteins in patients and / or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency.

This invention relates to the field of biomedical technology, and discloses a siRNA that specifically inhibits LILRB4 gene expression and its applications. The siRNA contains a completely inversely complementary sense strand and an antisense strand, the nucleotide sequences of which are any pair as shown in SEQ ID NO. 1 and 2, SEQ ID NO. 3 and 4, SEQ ID NO. 5 and 6, SEQ ID NO. 7 and 8, SEQ ID NO. 9 and 10, SEQ ID NO. 11 and 12, SEQ ID NO. 13 and 14, SEQ ID NO. 15 and 16, SEQ ID NO. 17 and 18, or SEQ ID NO. 19 and 20. This invention also provides the application of this siRNA in the preparation of pharmaceuticals. The siRNA pharmaceutical composition provided by this invention can effectively silence LILRB4 gene expression, inhibit the infiltration of tumor cells into normal tissues and organs, and enhance T cell activity.

This invention provides an siRNA that inhibits the expression of the MMP7 gene, comprising a sense strand and an antisense strand. The siRNA according to this invention has good stability, excellent MMP7 gene inhibitory activity, negligible cytotoxicity and immunostimulant activity, and can significantly reduce MMP7 protein levels at the animal level. It has significant clinical value in the treatment of diseases or conditions that benefit from the reduction of MMP7 levels or inhibition of its expression.